Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25797602 | 0.95 | MAOB (0.58) | MAOBMAOAPPARDPTPN11 | |
| SCHEMBL26331469 | 0.95 | MAOB (0.58) | MAOBMAOAPPARDPTPN11 | |
| SCHEMBL1415014 | 0.93 | MAOB (0.58) | MAOBMAOAPPARDMCL1 | |
| SCHEMBL5711594 | 0.87 | MAOB (0.74) | MAOBMAOAPPARD | |
| SCHEMBL1576849 | 0.87 | MCL1 (0.69) | MCL1PTPN11 | |
| SCHEMBL29623897 | 0.87 | MCL1 (0.69) | MCL1PTPN11 | |
| SCHEMBL3652542 | 0.86 | MAOB (0.61) | MAOBMAOA | |
| SCHEMBL8787008 | 0.86 | MAOB (0.55) | MAOBMAOAPPARD | |
| SCHEMBL25797604 | 0.86 | MAOB (0.55) | MAOBMAOAPPARD | |
| SCHEMBL28474199 | 0.85 | MAOB (0.57) | MAOBMAOAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016180349-A1 | BIPHENYL DERIVATIVE HAVING BETA2 RECEPTOR EXCITEMENT AND M RECEPTOR ANTAGONISTIC ACTIVITIES AND APPLICATION THEREFOF IN MEDICAMENT | 四川海思科制药有限公司 | 2016-11-17 | — | — | WO | disclosed |
| EP-1917253-B1 | METHOD FOR PRODUCING BETAMIMETICS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-8420809-B2 | Process for the manufacturing of betamimetics | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2125759-B1 | METHOD FOR PRODUCING BETAMIMETICS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110124859-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-26 | — | — | US | disclosed |
| WO-2008090193-A2 | METHOD FOR PRODUCING BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | WO | disclosed |
| US-20070088160-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| WO-2007020227-A1 | METHOD FOR PRODUCING BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088160-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | ADRA1D, ADRB1, ADRA1A | MAOB 200/4885MAOA 175/4885PPARD 2878/4885 |
| US-20110124859-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | ADRA1D, ADRB1, ADRA1A | MAOB 200/4885MAOA 175/4885PPARD 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.